Meyer Handelman Co. Trims Stake in Zimmer Biomet Holdings, Inc. $ZBH

Meyer Handelman Co. lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.3% in the 4th quarter, Holdings Channel reports. The fund owned 29,169 shares of the medical equipment provider’s stock after selling 5,700 shares during the quarter. Meyer Handelman Co.’s holdings in Zimmer Biomet were worth $2,623,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ZBH. Mn Services Vermogensbeheer B.V. raised its holdings in Zimmer Biomet by 0.9% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 76,244 shares of the medical equipment provider’s stock worth $6,856,000 after purchasing an additional 644 shares in the last quarter. Eastern Bank boosted its holdings in shares of Zimmer Biomet by 4.5% during the 4th quarter. Eastern Bank now owns 3,740 shares of the medical equipment provider’s stock valued at $336,000 after buying an additional 160 shares in the last quarter. Dakota Wealth Management grew its position in shares of Zimmer Biomet by 12.8% in the 4th quarter. Dakota Wealth Management now owns 11,831 shares of the medical equipment provider’s stock worth $1,064,000 after buying an additional 1,342 shares during the period. Corbyn Investment Management Inc. MD grew its position in shares of Zimmer Biomet by 4.5% in the 4th quarter. Corbyn Investment Management Inc. MD now owns 33,867 shares of the medical equipment provider’s stock worth $3,045,000 after buying an additional 1,447 shares during the period. Finally, Czech National Bank increased its stake in shares of Zimmer Biomet by 3.9% in the 4th quarter. Czech National Bank now owns 52,257 shares of the medical equipment provider’s stock worth $4,699,000 after acquiring an additional 1,944 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 1.9%

ZBH stock opened at $90.26 on Wednesday. The stock has a market capitalization of $17.66 billion, a P/E ratio of 25.50, a P/E/G ratio of 1.81 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The business has a fifty day moving average price of $92.09 and a 200-day moving average price of $93.81.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period last year, the company earned $2.31 EPS. Zimmer Biomet’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is currently 27.12%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ZBH shares. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. Finally, Sanford C. Bernstein upped their price target on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.